SS-31 (Elamipretide): research, prices and suppliers

Regulatory context

Elamipretide is investigated in mitochondrial research. The FDA records accelerated US approval of the medicine Forzinity on 19 September 2025 for Barth syndrome. The previous blanket statement “not approved” was therefore incorrect. This approval concerns that medicine and its specified conditions, not arbitrary research batches sold as SS-31.

FDA · 2025-09-19

Facts

• CAS number: 736992-21-5
• Molecular weight: 639.8 g/mol
• Amino acids: 4
• Purity specification: ≥ 98 % (HPLC, commercial standard)

Evidence

• A randomized, placebo-controlled phase 3 trial in people with primary mitochondrial myopathy did not meet its predefined primary endpoints on either the 6-minute walk test or the fatigue score, though the study drug was described as well tolerated. Karaa et al. 2023, Neurology, PMID 37268435
• A placebo-controlled phase 1 trial with stepwise increasing infusion amounts in people with heart failure and reduced ejection fraction described a single infusion of elamipretide as safe and well tolerated. Daubert et al. 2017, Circulation: Heart Failure, PMID 29217757
• A study in rats with cardiac ischemia-reperfusion injury described a significantly smaller infarct area when SS-31 was given beforehand compared with control animals. Cho et al. 2007, Coronary Artery Disease, PMID 17429296

Documented prices

Prices are recorded snapshots. Each entry states its date, currency and pack variant. Shipping, tax treatment, discount conditions and availability must be rechecked in the shop. A low price is not evidence of quality.

List prices excluding shipping and discounts. Currency and product variants must be compared separately. Availability and delivered batch have not been verified.

Questions about interpretation

Sources and data basis

These references come from the existing dataset. A link alone verifies neither a study claim nor supplier quality. Uncertainty remains explicit where records are undated or incomplete.

• Karaa et al. 2023, Neurology, PMID 37268435
• Daubert et al. 2017, Circulation: Heart Failure, PMID 29217757
• Cho et al. 2007, Coronary Artery Disease, PMID 17429296
• PMID 37268435
• PMID 29217757
• PMID 17429296

Where to go next

• MOTS-c
• Epitalon
• Dihexa
• Compare documented prices
• Particle Peptides
• Europa-Peptide
• BioCollex
• Smart Peptides
• Peak Peptide
• Beyond Peptides
• Licensed Peptides
• Bio BoostX
• American Peptides
• DN Lab Research
• Peptide Labz
• Peptide Shop Deutschland
• Read a COA: purity, amount and identity
• Our assessment methodology
• Look up recorded batches
• Look up terms in the glossary